CoChat
Sign Up
Cited by 224Antimicrobial Resistance in StaphylococcusAntibiotic Resistance in BacteriaAntibiotic Use and Resistance

The DOI matches its Crossref record; 123 of the 124 references it cites were found in a registry or an index.

Linezolid update: Stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms

Mendes, Rodrigo E., Deshpande, Lalitagauri M., Jones, Ronald N.·2014·Drug Resistance Updates
DOI 10.1016/j.drup.2014.04.002
Open this paper in CoChat — free account

Abstract

Linezolid, approved for clinical use since 2000, has become an important addition to the anti-Gram-positive infection armamentarium. This oxazolidinone drug has in vitro and in vivo activity against essentially all Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). The in vitro activity of linezolid was well documented prior to its clinical application, and several ongoing surveillance studies demonstrated consistent and potent results during the subsequent years of clinical use. Emergence of resistance has been limited and associated with invasive procedures, deep organ involvement, presence of foreign material and mainly prolonged therapy. Non-susceptible organisms usually demonstrate alterations in the 23S rRNA target, which remain the main resistance mechanism observed in enterococci; although a few reports have described the detection of cfr-mediated resistance in Enterococcus faecalis. S. aureus isolates non-susceptible to linezolid remain rare in large surveillance studies. Most isolates harbour 23S rRNA mutations; however, cfr-carrying MRSA isolates have been observed in the United States and elsewhere. It is still uncertain whether the occurrences of such isolates are becoming more prevalent. Coagulase-negative isolates (CoNS) resistant to linezolid were uncommon following clinical approval. Surveillance data have indicated that CoNS isolates, mainly Staphylococcus epidermidis, currently account for the majority of Gram-positive organisms displaying elevated MIC results to linezolid. In addition, these isolates frequently demonstrate complex and numerous resistance mechanisms, such as alterations in the ribosomal proteins L3 and/or L4 and/or presence of cfr and/or modifications in 23S rRNA. The knowledge acquired during the past decades on this initially used oxazolidinone has been utilized for developing new candidate agents, such as tedizolid and radezolid, and as linezolid patents soon begin to expire, generic brands will certainly become available. These events will likely establish a new chapter for this successful class of antimicrobial agents.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.drup.2014.04.002

Cites

123 of 123 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 124 references

Research works printed but not linked: 1

  1. Gales, 2014, Fatal pneumonia due to methicillin-susceptible Staphylococcus aureus ST398/t034 carrying cfr and erm(B) genes: first report in Brazil, J. Antimicrob. Chemother.

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Mendes, R. E., Deshpande, L. M., & Jones, R. N.
Affiliations
  • JMI Laboratories (US)
  • Tufts University (US)
Corresponding author
Mendes, Rodrigo E.
ORCID
Venue
Drug Resistance Updates
Publisher
Elsevier BV
Published
2014-04
Volume
17
Issue
1-2
Pages
1-12
ISSN
1368-7646 (ISSN-L)
DOI
10.1016/j.drup.2014.04.002
OpenAlex
W1977069647
Cited by
221
References
124
Citations by year
2026: 7 · 2025: 9 · 2024: 13 · 2023: 12 · 2022: 18 · 2021: 20 · 2020: 21 · 2019: 25 · 2018: 25 · 2017: 23 · 2016: 23 · 2015: 19 · 2014: 6
FWCI
3.29
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Drug Resistance Updates (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
  • Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
Keywords
linezolid, oxazolidinones, antimicrobial resistance, 23S rRNA mutations, cfr gene, methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, coagulase-negative staphylococci, Staphylococcus epidermidis, antimicrobial resistance surveillance, tedizolid, Gram-positive bacterial infections
MeSH terms
Linezolid, Acetamides, Ribosomal Protein L3, Anti-Bacterial Agents, Bacterial Proteins, Gram-Positive Bacteria, Humans, Microbial Sensitivity Tests, Mutation, Ribosomal Proteins, RNA, Ribosomal, 23S, Tetrazoles, Gram-Positive Bacterial Infections, Drug Approval, Oxazolidinones, Drug Resistance, Bacterial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review